Canaccord Genuity Initiates Coverage On Endo International plc - Ordinary Shares to Hold

One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -7.86% to close at $6.21 with the total traded volume of 3 Million shares. Endo International PLC has recorded a 50-day average of $13.45 and a two hundred day average of $17.66. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The company's market cap is $2.81 billion. Citigroup Downgrades the stock to Neutral on 1/05/17 by stationing a price target of $20. The rating by the stock financial advisor at Canaccord Genuity was issued on Feb 22, 2017 in a research report to their Investors and Clients.

Endo International plc - Ordinary Shares Last issued its quarterly earnings results on Nov 8, 2016.

"Endo International PLC (ENDP) Scheduled to Post Quarterly Earnings on Tuesday" was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.20. According to Zacks Investment Research, based on 10 analysts' forecasts, the consensus EPS forecast for the quarter is $1.63. Barclays PLC decreased their price target on shares of Endo International PLC from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, February 6th. While some analysts have a High Price target for the stock of $35 and a Low Price Target of $12. The stock touched its 52-Week High on Feb 26, 2016 and 52-Week Low on Jan 30, 2017.

Endo International plc (NASDAQ:ENDP) is now showing its ROA (Return on Assets) of -0.7%. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. The Next Year EPS growth is -5.9%, Long term annual growth estimate of -2.5%, Annual EPS growth past 5 years of -4.18 percent. The reported EPS for the same quarter previous year was $1.36. The stock traded with the volume of 9.42 Million shares yesterday. The Company has 52-week high of $54.79 and 52-week low of $11.37. The Monthly and Yearly performances are 5.92 percent and -74.33 percent respectively. It fell short of earnings estimates on 1 occasions, and it has met expectations 0 time.

In related news, Director Roger H. Kimmel sold 14,000 shares of the company's stock in a transaction that occurred on Tuesday, November 15th.

Endo International plc is expected* to report earnings on 02/28/2017 before market open. Stock's weekly performance expressed up trend of 1.90%.

The Company now has ROA (Return on Assets) of 0 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

  • Julie Sanders